Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Larry McColloch who wrote (165)	2/26/1998 7:56:00 PM
From: Bill Wexler	Read Replies (2) \| Respond to of 4634

Your guess is as good as mine about the speed of the fall. However, the fundamentals don't support more than a buck a share. FDA approval or denial isn't even an issue. The bottom line is that even with FDA approval, Biotime will be competing in a relatively small commodity market. If you examine the deal they made with Abbot closely, it is crystal clear that Abbot understands the true scope of the market. Biotime's shares became grossly overvalued because management was falsely promoting Hextend as a significantly better blood volume expander solution - with a much larger potential market.